We compared the aqueous profiles, baseline characteristics, and clinical outcomes of 54 eyes with macular edema secondary to major branch retinal vein occlusion (BRVO) and macular BRVO. We also identified the characteristics of poor responders to anti-vascular endothelial growth factor (VEGF) injections. Aqueous inflammatory cytokine and VEGF concentrations were significantly higher in major BRVO. In optical coherence tomography, major BRVO had a higher proportion with subretinal fluid, disorganization of retinal inner layers, and ellipsoid zone disruption. Comparing the clinical outcomes, major BRVO required more intravitreal anti-VEGF injections and had a poorer visual prognosis in the first 12 months. A significantly higher proportion of patients with major BRVO required additional treatments after 6 months compared to macular BRVO. Patients who responded poorly to anti-VEGF had higher aqueous VEGF levels and central subfield thickness (CST) at baseline. In conclusion, major BRVO patients required more and longer treatments, and had worse visual prognoses. BRVO that responds poorly to anti-VEGF had greater CST and higher aqueous VEGF levels at baseline.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388567 | PMC |
| http://dx.doi.org/10.1038/s41598-022-18414-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Endothelial Glycocalyx Damage and Arterial Thickness in Patients with Retinal Vein Occlusion (RVO).
J Clin Med
December 2024
2nd Department of Ophthalmology, Attikon Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.
: Retinal vein occlusion (RVO) is a relatively uncommon condition with a complex pathophysiology. However, its association with traditional cardiovascular risk factors is well established. In this study, we compared arterial stiffness and endothelial function between patients with RVO and healthy controls.
View Article and Find Full Text PDFIntraocular complement activation is independent of systemic complement activation and is related to macular vascular remodelling in retinal vein occlusion.
BMC Ophthalmol
November 2024
Aier Academy of Ophthalmology, Central South University, Changsha, Hunan Province, 410083, China.
Background: Retinal vein occlusion (RVO) is a major cause of vision loss. The pathogenesis remains poorly defined although inflammation is known to play a critical role. In this study, we investigated the levels of complement proteins in the aqueous humour and plasma of RVO participants and the relationship between complement levels and retinal pathologies.
View Article and Find Full Text PDFPopulation Prevalence, Pattern and Associated Factors for Retinal Diseases at High Altitude in Nepal.
Clin Ophthalmol
September 2024
Department of Cornea, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Article Synopsis
- A study in high-altitude districts of Nepal aimed to evaluate the prevalence and factors related to retinal diseases among individuals aged 40 and older, highlighting the impact of hypoxia on eye health.
- Out of 338 participants, more than half were diagnosed with retinal disorders, with hypertensive retinopathy being the most prevalent condition, significantly linked to older age and hypertension.
- The findings indicate a need for improved access to eye care and education on managing hypertension among high-altitude populations to prevent and manage retinal diseases.
Systemic Risk Factors in Branch Retinal Vein Occlusion: a Comprehensive Review.
Maedica (Bucur)
June 2024
Department of Ophthalmology, University Hospital of Patras, Patras, Greece.
Background: Retinal vein occlusion (RVO) is a major cause of vision impairment globally. Obstruction in the retinal venous system is often due to thrombus formation at arteriovenous crossing points, leading to symptoms localized to the affected retinal area. Systemic conditions like hypertension, diabetes mellitus, dyslipidemia and heart disease are recognized risk factors for RVO, influencing the components of Virchow's triad.
View Article and Find Full Text PDFRelationship between retinal volume changes and the prognosis of BRVO-ME treated with ranibizumab.
Heliyon
August 2024
Department of Ophthalmology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, China.
Background: This study aimed to evaluate the efficacy of ranibizumab for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO-ME), changes in retinal volume and central retinal thickness (CRT) before and after therapy, and the connection between visual prognosis and changes in retinal volume.
Methods: The 120 patients(121 eyes) of BRVO-ME were recruited from July 2020 to October 2022 at the Affiliated Hospital of Weifang Medical University. The clinical data of patients were retrospectively examined for changes in best-corrected visual acuity (BCVA), retinal volume, and CRT at 1 day, 1 week, 1 month, 3 months, 6 months and 1year after treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!